Xeris Price To Sales Ratio from 2010 to 2025
| XERS Stock | USD 3.35 0.19 5.37% |
Price To Sales Ratio | First Reported 2010-12-31 | Previous Quarter 2.27 | Current Value 2.16 | Quarterly Volatility 22.07799662 |
Check Xeris Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Xeris Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 5.7 M, Depreciation And Amortization of 15.9 M or Interest Expense of 32.1 M, as well as many indicators such as Price To Sales Ratio of 2.16, Dividend Yield of 0.0 or Days Sales Outstanding of 154. Xeris financial statements analysis is a perfect complement when working with Xeris Pharmaceuticals Valuation or Volatility modules.
Xeris | Price To Sales Ratio |
Latest Xeris Pharmaceuticals' Price To Sales Ratio Growth Pattern
Below is the plot of the Price To Sales Ratio of Xeris Pharmaceuticals over the last few years. Price to Sales Ratio is figured by comparing Xeris Pharmaceuticals stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Xeris Pharmaceuticals sales, a figure that is much harder to manipulate than other Xeris Pharmaceuticals multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. It is a valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period. Xeris Pharmaceuticals' Price To Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Xeris Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 2.87 X | 10 Years Trend |
|
Price To Sales Ratio |
| Timeline |
Xeris Price To Sales Ratio Regression Statistics
| Arithmetic Mean | 23.47 | |
| Geometric Mean | 11.93 | |
| Coefficient Of Variation | 94.07 | |
| Mean Deviation | 17.60 | |
| Median | 34.65 | |
| Standard Deviation | 22.08 | |
| Sample Variance | 487.44 | |
| Range | 81.4397 | |
| R-Value | (0.62) | |
| Mean Square Error | 319.48 | |
| R-Squared | 0.39 | |
| Significance | 0.01 | |
| Slope | (2.89) | |
| Total Sum of Squares | 7,312 |
Xeris Price To Sales Ratio History
About Xeris Pharmaceuticals Financial Statements
Xeris Pharmaceuticals shareholders use historical fundamental indicators, such as Price To Sales Ratio, to determine how well the company is positioned to perform in the future. Although Xeris Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Xeris Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Xeris Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Price To Sales Ratio | 2.27 | 2.16 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Xeris Stock Analysis
When running Xeris Pharmaceuticals' price analysis, check to measure Xeris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xeris Pharmaceuticals is operating at the current time. Most of Xeris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xeris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xeris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xeris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.